Onyia Jude sold $1.7M of NBIX
Onyia Jude (Chief Scientific Officer) sold 11,000 shares of NEUROCRINE BIOSCIENCES INC (NBIX) at $155.53 ($1.71M total) on 2026-05-27 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure may slightly influence short-term sentiment, but it does not introduce new operational, clinical, or financial catalysts.
Market read
Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a fundamental repricing.
What to watch
10b5-1 plans can be routine and scheduled; without context on prior sales/buybacks or changes in option exercises, the signal is weak.
Background
SEC Form 4 reports insider transactions; this one is an open-market sale by the Chief Scientific Officer.
Ticker impact
Neurocrine Biosciences CSO Onyia Jude sold 11,000 shares in an open-market transaction worth about $1.71M, disclosed via SEC Form 4.
Low immediate price impact; any move is likely sentiment-driven and short-lived.
The filing is an ownership-change disclosure (not earnings/drug data), and it explicitly states a pre-arranged 10b5-1 plan, which reduces interpretive weight.
Market effects
Minimal; this is company-specific insider activity without new clinical/regulatory information.
None expected beyond NBIX-specific sentiment.
None expected.
Counterpoint
Because the sale is sizable in dollar terms, some traders may still interpret it as a risk-management signal despite the 10b5-1 label.
Key entities
- issuerNeurocrine Biosciences, Inc.
Subject of the insider transaction disclosure (NBIX).
- insiderOnyia Jude
Chief Scientific Officer who sold 11,000 shares under a pre-arranged 10b5-1 plan.
